CoChat
Sign Up
Cited by 217Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancerCancer Genomics and Diagnostics

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

Open access
Tie, Jeanne, Lipton, Lara, Desai, Jayesh, Gibbs, Peter, Jorissen, Robert N., Christie, Michael, Drummond, Katharine J., Thomson, Benjamin N.J., Usatoff, Valery, Evans, Peter M., Pick, Adrian W., Knight, Simon, Carne, Peter W.G., Berry, Roger, Polglase, Adrian, McMurrick, Paul, Zhao, Qi, Busam, Dana, Strausberg, Robert L., Domingo, Enric, Tomlinson, Ian P.M., Midgley, Rachel, Kerr, David, Sieber, Oliver M.·2011·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-10-1720

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Purpose: Oncogene mutations contribute to colorectal cancer development. We searched for differences in oncogene mutation profiles between colorectal cancer metastases from different sites and evaluated these as markers for site of relapse. Experimental Design: One hundred colorectal cancer metastases were screened for mutations in 19 oncogenes, and further 61 metastases and 87 matched primary cancers were analyzed for genes with identified mutations. Mutation prevalence was compared between (a) metastases from liver (n = 65), lung (n = 50), and brain (n = 46), (b) metastases and matched primary cancers, and (c) metastases and an independent cohort of primary cancers (n = 604). Mutations differing between metastasis sites were evaluated as markers for site of relapse in 859 patients from the VICTOR trial. Results: In colorectal cancer metastases, mutations were detected in 4 of 19 oncogenes: BRAF (3.1%), KRAS (48.4%), NRAS (6.2%), and PIK3CA (16.1%). KRAS mutation prevalence was significantly higher in lung (62.0%) and brain (56.5%) than in liver metastases (32.3%; P = 0.003). Mutation status was highly concordant between primary cancer and metastasis from the same individual. Compared with independent primary cancers, KRAS mutations were more common in lung and brain metastases (P < 0.005), but similar in liver metastases. Correspondingly, KRAS mutation was associated with lung relapse (HR = 2.1; 95% CI, 1.2 to 3.5, P = 0.007) but not liver relapse in patients from the VICTOR trial. Conclusions: KRAS mutation seems to be associated with metastasis in specific sites, lung and brain, in colorectal cancer patients. Our data highlight the potential of somatic mutations for informing surveillance strategies. Clin Cancer Res; 17(5); 1122–30. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-1720

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

Sorted by citations

Items 101–200 of 217

Related

See all

Metadata

Authors
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., Pick, A. W., Knight, S., Carne, P. W. G., Berry, R., Polglase, A., McMurrick, P., Zhao, Q., Busam, D., Strausberg, R. L., Domingo, E., Tomlinson, I. P. M., Midgley, R., Kerr, D., & Sieber, O. M.
Affiliations
  • J. Craig Venter Institute (US)
  • Authors' Affiliations: 1Ludwig Colon Cancer Initiative Laboratory, Ludwig Institute for Cancer Research; 2Faculty of Medicine, Dentistry and Health Sciences, Department of Surgery, University of Melbourne; 3Departments of Medical Oncology, 4Neurosurgery, and 5Surgery, Royal Melbourne Hospital, Parkville; 6Division of Surgical Oncology, Peter MacCallum Cancer Center, East Melbourne; 7Department of Surgery, Western Hospital, Footscray; 8Cabrini Monash University Department of Surgery, St Frances Xavier Cabrini Hospital, Malvern, Melbourne, Australia; 9J. Craig Venter Institute, Rockville, Maryland; 10Ludwig Institute for Cancer Research, New York, New York; 11Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics and 12Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2011-03-01
Volume
17
Issue
5
Pages
1122-1130
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-10-1720
OpenAlex
W2038202392
Cited by
217
References
50
Citations by year
2026: 9 · 2025: 4 · 2024: 9 · 2023: 18 · 2022: 7 · 2021: 13 · 2020: 13 · 2019: 17 · 2018: 11 · 2017: 19 · 2016: 15 · 2015: 21 · 2014: 20 · 2013: 16 · 2012: 21
FWCI
9.60
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
KRAS mutation, colorectal cancer, lung metastasis, liver metastasis, brain metastases, oncogenic mutations, BRAF, NRAS, PIK3CA, curative resection, somatic mutations, surveillance strategy
MeSH terms
Brain Neoplasms, Colonic Neoplasms, Female, Humans, Liver Neoplasms, Lung Neoplasms, Male, Mutation, Neoplasm Recurrence, Local, Proto-Oncogene Proteins, Genes, ras, Biomarkers, Tumor, Proto-Oncogene Proteins p21(ras), ras Proteins, Phosphatidylinositol 3-Kinases, Gene Expression Profiling, Proto-Oncogene Proteins B-raf, Microsatellite Instability, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review